JT
CLDX icon

Jupiter Topco’s Celldex Therapeutics CLDX Stock Holding History

Jupiter Topco’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
+30,042
New +$970K ﹤0.01% 1758

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco's CLDX Position: Q2 2026 in Review

Jupiter Topco opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 30,042 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #1758 among its holdings.

234 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Jupiter Topco held 30,042 shares of Celldex Therapeutics worth $1.12M as of Q2 2026.
  • Celldex Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #1758 holding.
  • 234 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.